Krystal Biotech Inc (KRYS) - Gross Profit Ratio

Corporate emblem and logo of Krystal Biotech Inc (KRYS)

Krystal Biotech, Inc. (KRYS) is scaling profits due to the low cost of goods sold for its gene gels following FDA approval. The gross margin reflects financial resilience, with the metric currently standing at 93.00. This confirms the founders' competence in commercializing therapies for orphan diseases. Current success is driven by sales of the first drug and stable insurance reimbursements.

krystalbio.com (KRYS) Gross Profitability: for the period 07/04/2022 - 11/20/2026

Financial and market metric breakdowns for Krystal Biotech, Inc. (KRYS)

- current quotes and average value forecast:
- market capitalization indicators:
Fundamental valuation:KRYS - Krystal Biotech Inc
Manufactured products of Krystal Biotech Corp.

Gross margin measures production efficiency by determining the portion of revenue remaining after direct costs, which is critical for assessing the fundamental viability of a business. An analysis of the gross profit margin allows for a comparison of Krystal Biotech, Inc. (KRYS) operational profitability against the high costs of gene therapy production and licensing, revealing the company's actual ability to overcome the financial uncertainty of product commercialization.